



**AUXLY CANNABIS GROUP INC.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND  
RESULTS OF OPERATIONS**

**FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023**

**Dated August 11, 2023**

## Table of Contents

<b>MANAGEMENT’S DISCUSSION AND ANALYSIS.....</b>	<b>3</b>
<b>DESCRIPTION OF BUSINESS.....</b>	<b>3</b>
<b>OUTLOOK.....</b>	<b>9</b>
<b>RECENT DEVELOPMENTS: SECOND QUARTER 2023 TO DATE.....</b>	<b>10</b>
<b>FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE INDICATORS.....</b>	<b>11</b>
<b>RESULTS OF OPERATIONS.....</b>	<b>12</b>
<b>SUMMARY OF QUARTERLY RESULTS .....</b>	<b>15</b>
<b>TRANSACTIONS WITH RELATED PARTIES.....</b>	<b>16</b>
<b>LIQUIDITY AND CAPITAL RESOURCES .....</b>	<b>16</b>
<b>OUTSTANDING SHARE DATA.....</b>	<b>18</b>
<b>NON-GAAP MEASURES.....</b>	<b>18</b>
<b>COMMITMENTS AND OFF-BALANCE SHEET ARRANGEMENTS.....</b>	<b>20</b>
<b>CRITICAL ACCOUNTING ESTIMATES.....</b>	<b>21</b>
<b>DISCLOSURE AND INTERNAL CONTROLS AND PROCEDURES.....</b>	<b>23</b>
<b>CHANGES IN ACCOUNTING POLICIES .....</b>	<b>24</b>
<b>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT .....</b>	<b>24</b>
<b>RISK FACTORS.....</b>	<b>24</b>
<b>FORWARD LOOKING STATEMENTS.....</b>	<b>25</b>

## MANAGEMENT'S DISCUSSION AND ANALYSIS

This Management's Discussion and Analysis ("MD&A") was prepared as of August 11, 2023 unless otherwise indicated. This MD&A reviews the operating results, financial position and liquidity of Auxly Cannabis Group Inc. ("**Auxly**", "**we**", "**our**", or the "**Company**"). All amounts are stated in millions of Canadian dollars unless otherwise noted, except common shares ("**Shares**"), options, warrants, and per Share amounts. This MD&A should be read in conjunction with the interim condensed consolidated financial statements and the notes thereto for the three and six months ended June 30, 2023, as well as the Company's audited consolidated financial statements and accompanying notes thereto and annual MD&A for the year ended December 31, 2022.

This MD&A may contain forward-looking information that is based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates. Forward-looking information contained herein is made as of the date of this MD&A and is not a guarantee of future performance and involves risks and uncertainties that are difficult to control or predict. Readers should refer to the "*Forward Looking Statements*" section in this MD&A. This MD&A references certain financial measures, including non-GAAP measures and readers should refer to the "*Non-GAAP Measures*" section in this MD&A.

## DESCRIPTION OF BUSINESS

### Our Business

We are a leading Canadian consumer packaged goods company in the cannabis products market, headquartered in Toronto, Canada. Our focus is on developing, manufacturing and distributing branded cannabis products that delight our consumers.

Our vision is to be a leader in branded cannabis products that deliver on our consumer promise of quality, safety and efficacy.

### Canadian Market

On October 17, 2018, the Cannabis Act came into force, initially permitting the recreational sale of certain classes of cannabis products, including dried cannabis, fresh cannabis, cannabis plants, cannabis seeds, and cannabis oil (collectively referred to as "**Cannabis 1.0 Products**"). On October 17, 2019, edible cannabis, cannabis extracts and cannabis topicals were added to the authorized classes of cannabis (collectively referred to as "**Cannabis 2.0 Products**", and together with Cannabis 1.0 Products, collectively referred to as "**Cannabis Products**") and such Cannabis 2.0 Products were first available for sale on December 16, 2019. Since 2019, Health Canada undertook a consultation, established a Scientific Advisory Committee, and has been engaged in discussions regarding the possible legalization of Cannabis Health Products, which would permit the making of health claims in respect of cannabis products without the required oversight of a practitioner, such as a doctor, but such products are not currently permitted.

## Canadian Strategy and Capabilities

### Brand Portfolio and Product Offering

We have created a portfolio of brands designed for a broad market of cannabis consumers, with differentiation in price points across targeted consumer segments.

Parcel

BACK FORTY

Foray



Dosecann

KOLAB PROJECT

## Our Brands

### PARCEL

Parcel delivers on its promise – high quality cannabis for less. No bells, no whistles, just really good cannabis grown by really good people.

### BACK FORTY

Take a Trip. Explore the Back Forty. Back Forty is all about embracing simplicity, getting back to basics and not taking life too seriously. Back Forty's mission is to bring to consumers a simple, uncomplicated cannabis product that already feels familiar.

### FORAY

Foray is a versatile, modern, and inviting cannabis brand, designed for the curious. Foray is an accessible entry point for anybody—at any stage of their cannabis journey. Designed for the curious, Foray is an approachable brand that aims to both celebrate and guide one's foray into cannabis, ultimately inviting them to see cannabis differently.

### DOSECANN

We believe in the natural potential of cannabis. Backed by science and advanced research and development, Dosecann products are driving today's innovation and establishing tomorrow's standards. Cannabis down to a science.

### KOLAB PROJECT

Offering a refined collection of high quality cannabis products and design-focused, purposeful goods. We connect consumers with a carefully selected group of collaborators in order to create experiences that are inspired by the ever-evolving world we live in.

Based upon consumer insights, Auxly has developed a broad portfolio of Cannabis Products to meet the evolving needs and preferences of Canadian cannabis consumers. Our initial focus was on the development of Cannabis 2.0 Products and we were one of the first cannabis companies to distribute and sell Cannabis 2.0 Products across Canada following their legalization.

We were the top-selling licensed producer of Cannabis 2.0 Products nationally for the past three years and have continued to introduce a variety of Cannabis Products to the market throughout 2023, ranking among the top 5 licensed producers in Canada by total recreational retail sales as reported by Hifyre IQ (“Hifyre IQ”)<sup>1</sup>.

Our Cannabis Products available during the second quarter of 2023 are described below by brand and product format:



Products Available by Brand				
KOLAB PROJECT	 Dosecann	BACK FORTY	Foray	Parcel
510 Vape Cartridges All-in-one Vape Pens Dried Flower Pre-rolled Cannabis Infused Pre-rolls Concentrates Soft Chews	Cannabis Oil Drops Capsules Topicals	510 Vape Cartridges Dried Flower Milled Flower Pre-rolled Cannabis Infused Pre-rolls Chocolates Soft Chews	510 Vape Cartridges All-in-one Vape Pens Chocolates Soft Chews	Dried Flower Milled Flower

Our Cannabis Products have been well received by consumers. We plan to further strengthen our brand recognition by using consumer insights to drive innovation as we continue to introduce new Cannabis Products to the Canadian market, with an emphasis on expanding our dried flower, vape and pre-roll offerings. The Company’s upcoming product offerings for 2023 are presented below:



<sup>1</sup> Data provided by HiFyre IQ as at July 31, 2023.

## ***Distribution***

Given the current provincial legislative framework in Canada, we have pursued a multifaceted strategy to gain access to Canadian consumers. This includes supply arrangements with provincial control boards and distributors, medical cannabis sales channels and strong relationships with major Canadian retailers. Prior to the fourth quarter of 2022, Auxly's sales were supported by an externally managed sales team, but the Company now conducts its sales through an internal sales team.

We have secured listings and sold our Cannabis Products in all provinces except Quebec. We have obtained the necessary pre-authorization to enter into public contracts in Quebec and continue to explore listings for certain products that comply with Quebec's regulatory requirements. In the fourth quarter of 2022, the Company began its first wholesale bulk sales of dried cannabis intended for sale in the Quebec market.

## ***Cannabis Operations: Cultivation, Product R&D and Manufacturing***

### Auxly Charlottetown

In May 2018, we acquired our subsidiary Auxly Charlottetown Inc. ("**Auxly Charlottetown**"), and its purpose-built, GMP-compliant cannabis processing facility located in Charlottetown, Prince Edward Island. The Company conducts its Cannabis 2.0 Product development, manufacturing and R&D activities in-house at the Auxly Charlottetown facility. Auxly Charlottetown holds licences for processing, analytical testing and research under the Cannabis Act. The full perimeter of the 52,000 square foot facility is currently licensed under the Cannabis Regulations for the production, storage and sale of Cannabis Products.

Product development is led by Auxly Charlottetown's team, who have experience in the pharmaceutical, food, scientific research and product development fields. As the Company's manufacturing hub, this facility provides the Company with the ability to be responsive to changing industry regulation and evolving consumer preferences. Auxly Charlottetown is authorized to conduct broad in-house analytical and sensory testing, incorporating consumer input and feedback on attributes such as flavour, aroma, texture or mouthfeel, to better evaluate later-stage product formulations. In December 2022, the Company also obtained a research licence to conduct sensory testing at its head office in Toronto.

As at June 30, 2023, \$0.1 million of expenditures were made towards automation initiatives at the Auxly Charlottetown facility. The Company anticipates that expenditures of approximately \$Nil-0.5 million will be made towards the purchase of automation equipment, the expansion of throughput capabilities and security enhancements at the facility in 2023.

### Auxly Ottawa

In 2020, the Company ceased cultivation at Auxly Ottawa Inc.'s ("**Auxly Ottawa**") 10,000 sq. ft. facility and shifted its focus to the manufacturing, processing and distribution of dried flower and pre-roll cannabis products. Since acquiring Auxly Leamington Inc. ("**Auxly Leamington**") in November 2021, the Company has scaled up cultivation and post-harvest operations and fully built out manufacturing, processing and distribution capabilities at Auxly Leamington to be able to handle the same activities conducted at Auxly Ottawa.

On May 30, 2023, Auxly announced that it had transitioned all remaining dried flower and pre-roll cannabis product manufacturing, processing and distribution activities from its Auxly Ottawa facility to the Auxly Leamington facility. This includes the production of the Company's Cannabis 1.0 Products, including Kolab Project 950 Series dried flower and pre-rolls, Back Forty 40s pre-

rolls, and Back Forty and Parcel dried and milled flower. The Company will continue to wind-down its Auxly Ottawa facility in an orderly manner and intends to sell Auxly Ottawa's assets in due course and apply the proceeds from any such sale to support its ongoing operations, see “*Recent Developments: Second Quarter 2023 To Date – Auxly Furthers Manufacturing Optimization Plan and Related Cost Savings Initiatives*” in this MD&A.

### Auxly Leamington

We simplified our cultivation supply chain through the acquisition of 100% of Auxly Leamington on November 22, 2021. Auxly Leamington provides the Company with a secure and cost-efficient source of dried cannabis, milled flower and extraction materials. Prior to the acquisition of Auxly Leamington, the Company was dependent on third party wholesale purchases. Auxly also began its first wholesale bulk cannabis sales from the Auxly Leamington facility starting in the fourth quarter of 2022 and has continued its wholesale bulk cannabis sales throughout 2023.

Auxly Leamington is comprised of a 1.1 million square foot automated greenhouse in Leamington, Ontario, which holds licences for cultivation and processing under the Cannabis Act, authorizing the cultivation, processing, storage and sale of Cannabis Products. Auxly Leamington utilizes a perpetual harvest methodology resulting in a continuous supply of cannabis and flexibility to adjust production capacity to demand as required. On October 26, 2022, Auxly Leamington received approval under the Cannabis Act for an additional cannabis storage area, resulting in a 12,156 square foot expansion of its licensed perimeter. Auxly Leamington intends to use this environmentally controlled expansion to increase its storage and manufacturing capabilities. The total area of the licensed perimeter at Auxly Leamington for cultivation, processing and storage stands at 876,270 square feet. Auxly Leamington is producing award-winning cannabis strains, including popular Back Forty strains and high-quality value strains under the newly launched brand Parcel, all of which are sold to and used by the Company in its full suite of Cannabis Products across all Auxly brands. In addition, Auxly Leamington possesses an extensive genetic library and continues to evaluate all opportunities to acquire new cultivars suited for Auxly's portfolio of Cannabis Products.

As at June 30, 2023, expenditures of approximately \$0.6 million were made towards capacity expansion, equipment and post-harvest automation. We expect to incur expenditures of approximately \$2.0-3.0 million towards capital projects throughout 2023 and 2024 to increase staff housing, implement alternate post-harvest drying methods and purchase equipment to support higher output from the facility.

Over the past three years, the Company undertook new capital projects to increase pre-roll production volumes and output through the purchase, installation and commissioning of automated manufacturing and packaging equipment. Supply chain issues resulted in significant delays in receipt of both the manufacturing equipment and the technical support required to complete commissioning for full scale production. The pre-roll packaging automation equipment is operational and the Company saw increased production in Q2 2023 and we expect to see continued increases through the remainder of the year. The Company continues to work closely with the manufacturer as the packaging equipment is currently operating below specification. On May 30, 2023, the Company announced that it had transitioned all remaining pre-roll cannabis product manufacturing, processing and distribution activities from its Auxly Ottawa facility to Auxly Leamington. As at June 30, 2023, expenditures of approximately \$0.3 million were made towards dried flower and pre-roll automation initiatives. We expect to incur expenditures of approximately

\$2.5-3.5 million towards capital projects focused on pre-roll cannabis filling machinery and dried flower and pre-roll packaging automation.

Funding for the initial project budget was provided by the Company in the form of an equity contribution and a subordinated promissory note totaling approximately \$98.5 million provided prior to 2020, and an \$84 million secured credit facility underwritten by a syndicate of lenders led by the Bank of Montreal ("**BMO**"). The Company's contribution along with the credit facility comprised the required expenditures for the initial budgeted construction of the facility. Concurrently with the Auxly Leamington acquisition, the Company and Auxly Leamington amended and restated the secured credit facility with BMO and the same syndicate of lenders thereby remedying the defaults noted by BMO on April 16, 2021. Under the amended and restated secured credit agreement ("**ARCA**"), Auxly made a \$15 million cash payment towards the outstanding principal balance of the credit facility and the maturity date of the credit facility was extended to September 30, 2023. The obligations of Auxly Leamington under the credit facility also continue to be supported by an unsecured \$33 million limited resource guarantee provided by the Company.

Auxly Leamington informed the syndicate of lenders that it did not wish to exercise its option to extend the maturity date for an additional year by making a further principal repayment of \$5 million by September 30, 2022. As at June 30, 2023, Auxly Leamington was in compliance with its covenants under the credit facility, including all financial covenants, and discussions with the lenders with respect to a formal credit amendment have commenced although there can be no assurance that an agreement with the lenders will be reached. Upon filing the Company's financial statements for the year ended December 31, 2022, and delivering the audited financial statements for Auxly Leamington for the year ended December 31, 2022, each of the Company and Auxly Leamington was in breach of certain reporting covenants under the ARCA due to the inclusion of going concern qualifications in such reports. The Company and Auxly Leamington have received a waiver from the syndicate of lenders for such breaches.

#### Auxly Annapolis and Auxly Annapolis OG

On February 7, 2022, Auxly announced that it had ceased operations at the Auxly Annapolis Inc. ("**Auxly Annapolis**") and Auxly Annapolis OG Inc. ("**Auxly Annapolis OG**") facilities and its intention to divest of these non-core assets and apply the proceeds from any such sale to support its ongoing operations. On July 5, 2022, Auxly announced that it had closed the sale of the Auxly Annapolis indoor facility to a private purchaser for total proceeds of \$6 million. On August 10, 2022, Auxly announced that it had closed the sale of the Auxly Annapolis OG outdoor facility to a private purchaser for total proceeds of \$4.1 million.

#### ***Strategic Partner***

##### Imperial Brands

Through our strategic partnership with Imperial Brands PLC ("**Imperial Brands**"), Auxly was granted global licenses to Imperial Brands vaping technology for cannabis uses, and access to its vapour innovation business, Nerudia, and Imperial Brands will use Auxly as its exclusive partner for the future development, manufacture, commercialization, sale and distribution of cannabis products of any kind anywhere in the world. In connection with the strategic partnership with Imperial Brands, the parties entered into an investor rights agreement (the "**Investor Rights Agreement**") which provides, among other things, that for so long as Imperial Brands holds a partially diluted percentage of outstanding common shares in the capital of Auxly of not less than 15%, it is eligible to nominate one individual designated by Imperial Brands for election as a

director to Auxly's Board and one non-voting observer. As Imperial Brands no longer holds the required percentage under the Investor Rights Agreement, its nominee, Murray McGowan, Chief Strategy and Development Officer for Imperial Brands, who was appointed to Auxly's Board of Directors on November 1, 2021, resigned from the Board on July 26, 2023. see "*Recent Developments: Second Quarter 2023 To Date – Imperial Brands Extends \$123 million Convertible Debenture and Auxly Implements Board and Management Changes*" in this MD&A.

### ***International Operations***

Presently the Company does not have any active international operations. In the third quarter of 2020, the Company ceased all activities at its subsidiary Inverell S.A. ("**Inverell**") in Uruguay due to the slower than anticipated pace of cannabis-specific regulatory development in Latin America. Auxly is continuing to monitor the progress of other jurisdictions towards recreational and medical cannabis legalization, including the United States and Europe.

## **OUTLOOK**

In 2023, we aim to continue to improve earnings performance, increase focus on key product formats, lower costs and increase efficiency, which we expect will yield positive results. With these actions in mind, our goals for 2023 are broadly defined below:

- Increase net revenues by 15%, with a focus on key product categories, enhanced by strategic expansion of our product portfolio, while supporting strong retail distribution through our internal sales team.
- Continue to leverage Auxly Leamington's large-scale, low-cost cultivation facility and the Company's manufacturing automation to increase blended Cost of Finished Cannabis Inventory Sold Margin to an average of 35-40%.
- Vigorously manage SG&A as a percentage of net revenues to keep it below 40%.
- Prudently manage the Company's balance sheet and streamline assets where possible.

In the second quarter of 2023, the Company continued to focus on simplifying and streamlining its business to improve operating efficiency and reduce costs. The Company successfully transitioned all functions previously conducted at its Auxly Ottawa facility to its Auxly Leamington facility, and is in the process of winding down and disposing of Auxly Ottawa's assets. While the transition had a temporary impact on the Company's sales and financial performance during the quarter, it allowed the Company to better tailor its workforce and operations and has resulted in increased throughput and product quality which the Company believes will improve its pre-roll and dried flower product category performance in the near term. The results for the second quarter of 2023 were also negatively impacted by price compression in the adult-use recreational market as the customer and product mix evolved to focus more on value offerings, and by increased competition in the value price segment, particularly in the 28 gram dried flower format. The Company believes that it is well-positioned to compete in the value price segment given its brand portfolio and Auxly Leamington's cost structure and has taken steps to adjust existing product pricing where necessary and increase distribution for its Parcel branded products. Despite lower sales and gross profits in the second quarter compared to the first quarter, the Company made material improvements in its SG&A by reducing overhead in the organization and will continue to actively manage spending while looking for further cost reduction opportunities.

We continue to work towards achievement of our full year plan, built upon proven demand for our products, outstanding employees, top-tier assets and an underlying desire to continue to put our consumers first by delivering safe, effective, high-quality products that address their evolving needs and preferences and help them live happier lives.

## **RECENT DEVELOPMENTS: Second Quarter 2023 To Date**

### *Imperial Brands Extends \$123 million Convertible Debenture and Auxly Implements Board and Management Changes*

On July 26, 2023, the Company announced an agreement with Imperial Brands to amend certain provisions of its previously issued \$123 million debenture dated September 25, 2019 as amended on July 6, 2021. Imperial Brands and the Company have agreed to extend the maturity date of the debenture by 24 months from September 25, 2024 to September 25, 2026. The parties anticipate the amendment to come into effect on August 16, 2023.

The debentures are convertible into Shares at a price of \$0.81 per Share at any time prior to the close of business on the business day immediately preceding maturity. Auxly remains Imperial Brands' exclusive global partner for any future development, manufacture, commercialization, sale and distribution of cannabis products. In connection with the initial investment by Imperial Brands, the parties entered into the Investor Rights Agreement which provides, among other things, that for so long as Imperial Brands holds a partially diluted percentage of outstanding common Shares in the capital of Auxly of not less than 15%, it is eligible to nominate one individual designated by Imperial Brands for election as a director to Auxly's Board. As Imperial Brands no longer holds the required percentage under the Investor Rights Agreement, its nominee, Murray McGowan, has resigned from Auxly's Board effective immediately.

The Company also announced the resignation of Mr. Brian Schmitt from his position as Chief Financial Officer ("**CFO**") of Auxly, effective July 26, 2023. Mr. Schmitt is leaving for an opportunity outside of the cannabis industry at a non-reporting issuer. Travis Wong, Auxly's Senior Vice President of Finance, has been appointed interim CFO of Auxly effective immediately.

As at July 26, 2023, the Company has received all necessary approvals required to implement the warrant amendments that were previously announced on February 10, 2023, and such warrant amendments are effective as of July 14, 2023. The Company amended the terms of 27,381,500 common share purchase warrants which were issued pursuant to a bought deal financing completed on June 14, 2021 to (i) reduce the exercise price to \$0.045 per common share, and (ii) extend the expiry date to June 14, 2026. None of the warrants are held, directly or indirectly, by insiders.

### *Auxly Furthers Manufacturing Optimization Plan and Related Cost Savings Initiatives*

On May 30, 2023, the Company announced that it had transitioned all remaining dried flower and pre-roll cannabis product manufacturing, processing and distribution activities from its Auxly Ottawa facility to Auxly Leamington. The Company will continue to wind-down its Auxly Ottawa facility in an orderly manner and intends to sell Auxly Ottawa's assets in due course and apply the proceeds from any such sale to support its ongoing operations. This strategic decision comes after careful consideration in identifying opportunities to optimize operations and effectively reduce operating costs, while increasing product quality and ensuring no material impact on the Company's manufacturing capabilities and forecasted sales revenue.

## FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE INDICATORS

For the three months ended: (000's)	June 30, 2023	June 30, 2022	Change	Change
Total net revenues	21,990	27,335	(5,345)	-20%
Net income/(loss)	(12,863)	(14,289)	1,426	10%
Adjusted EBITDA*	(1,078)	(3,995)	2,917	73%
Weighted average shares outstanding	1,002,014,308	888,266,729	113,747,579	13%

For the six months ended: (000's)	June 30, 2023	June 30, 2022	Change	Change
Total net revenues	45,958	49,961	(4,003)	-8%
Net income/(loss)	(23,112)	(54,135)	31,023	57%
Adjusted EBITDA*	(940)	(10,319)	9,379	91%
Weighted average shares outstanding	978,146,905	875,843,490	102,303,415	12%

As at: (000's)	June 30, 2023	December 31, 2022	Change	Change
Cash and equivalents	\$ 8,557	\$ 14,636	\$ (6,079)	-42%
Total assets	\$ 316,890	\$ 331,820	\$ (14,930)	-4%
Debt**	\$ 174,201	\$ 174,475	\$ (274)	0%

\*Adjusted EBITDA is a Non-IFRS financial measure. Refer to the Non-GAAP Measures section for definitions.

\*\*Debt is a supplementary financial measure. Refer to the Non-GAAP Measures section for definitions.

For the period ended June 30, 2023, net revenues were \$22.0 million, a decrease of approximately \$5.3 million or 20% over the same period of 2022. The sales decline is primarily driven by price compression in the adult-use recreational market as the customer and product mix evolved to focus more on value offerings.

Net losses of \$12.9 million decreased by \$1.4 million over the same period in 2022, primarily due to improved operating results in 2023 that were partially offset by losses of \$2.6 million associated with the transition of the Company's dried flower and pre-roll cannabis product manufacturing to the Auxly Leamington facility in 2023.

Adjusted EBITDA was negative \$1.1 million for the quarter, an improvement of \$2.9 million when compared to negative \$4.0 million during the same period of 2022. Adjusted EBITDA for the three months ended June 30, 2023 improved primarily as a result of SG&A reductions, partially offset by lower gross profits. Adjusted EBITDA for the six months ended June 30, 2023 increased by \$9.4 million as compared to the same period of 2022 primarily as a result of improved gross profits and lower SG&A.

For the period ended June 30, 2023, the average number of Shares outstanding increased to 1.0 billion Shares, an increase of 113.7 million Shares or 13% over 2022 primarily as a result of the full year impact of Shares issued in 2022 and Shares issued in connection with the February 2023 private placement.

Cash and equivalents were \$8.6 million on June 30, 2023, a decrease of \$6.1 million from December 31, 2022. The change in cash was primarily associated with decreases in cash provided by operating activities and financing activities, offset by net proceeds from the February 2023 private placement.

## RESULTS OF OPERATIONS

For the periods ended: (000's)	Three months June 30,		Six months June 30,	
	2023	2022	2023	2022
<b>Revenues</b>				
Revenue from sales of cannabis products	\$ 34,514	\$ 40,088	\$ 72,058	\$ 73,292
Excise taxes	(12,524)	(12,753)	(26,100)	(23,331)
<b>Total net revenues</b>	<b>21,990</b>	<b>27,335</b>	<b>45,958</b>	<b>49,961</b>
<b>Costs of sales</b>				
Costs of finished cannabis inventory sold	16,035	20,574	31,060	38,096
Biological asset impairment	-	-	-	704
Inventory impairment	1,459	1,778	2,132	6,656
<b>Gross profit/(loss) excluding fair value items</b>	<b>4,496</b>	<b>4,983</b>	<b>12,766</b>	<b>4,505</b>
Unrealized fair value gain/(loss) on biological transformation	4,713	11,735	8,960	18,208
Realized fair value gain/(loss) on inventory	(3,146)	(6,898)	(7,785)	(9,223)
<b>Gross profit</b>	<b>6,063</b>	<b>9,820</b>	<b>13,941</b>	<b>13,490</b>
<b>Expenses</b>				
Selling, general, and administrative expenses	8,810	12,936	18,900	25,575
Equity-based compensation	377	2,916	786	3,119
Depreciation and amortization	1,673	3,900	3,418	8,500
Interest and accretion expense	6,457	5,336	12,265	10,416
<b>Total expenses</b>	<b>17,317</b>	<b>25,088</b>	<b>35,369</b>	<b>47,610</b>
<b>Other income/(loss)</b>				
Interest and other income	(20)	84	(6)	169
Impairment of assets	(2,588)	-	(2,588)	(23,673)
Gain/(loss) on settlement of assets and liabilities and other expenses	1,478	(1,987)	1,478	(1,987)
Gain on disposal of assets held for sale	-	2,150	-	2,150
Foreign exchange gain/(loss)	(479)	647	(568)	286
<b>Total other income/(loss)</b>	<b>(1,609)</b>	<b>894</b>	<b>(1,684)</b>	<b>(23,055)</b>
<b>Net loss before income tax</b>	<b>(12,863)</b>	<b>(14,374)</b>	<b>(23,112)</b>	<b>(57,175)</b>
Income tax recovery	-	85	-	3,040
<b>Net income/(loss)</b>	<b>\$ (12,863)</b>	<b>\$ (14,289)</b>	<b>\$ (23,112)</b>	<b>\$ (54,135)</b>
<b>Adjusted EBITDA</b>	<b>\$ (1,078)</b>	<b>\$ (3,995)</b>	<b>\$ (940)</b>	<b>\$ (10,319)</b>
<b>Net income/(loss) per common share (basic and diluted)</b>	<b>\$ (0.01)</b>	<b>\$ (0.02)</b>	<b>\$ (0.02)</b>	<b>\$ (0.06)</b>
<b>Weighted average shares outstanding (basic and diluted)</b>	<b>1,002,014,308</b>	<b>888,266,729</b>	<b>978,146,905</b>	<b>875,843,490</b>

## **Net Revenues**

For the three and six months ended June 30, 2023, net revenues were \$22.0 million and \$46.0 million as compared to \$27.3 million and \$50.0 million during the same period in 2022, a decline of 20% and 8% respectively. Revenues for the three and six months ended June 30, 2023 were comprised of approximately 50% in sales of dried flower and pre-roll Cannabis Products, with the remainder from oils and Cannabis 2.0 Product sales. Net revenues included wholesale bulk flower sales of approximately \$1.9 million and \$2.9 million during the three and six months ended June 30, 2023. Auxly maintained its position as a top 5 LP, by maintaining strength in sales of both Cannabis 1.0 and Cannabis 2.0 Products<sup>2</sup>.

Consistent with prior periods, as the Company does not participate in the Quebec market, approximately 85% of cannabis sales during the period originated from sales to British Columbia, Alberta and Ontario.

## **Gross Profit**

Auxly realized a gross profit of \$6.1 million and \$13.9 million for the three and six months ending June 30, 2023 resulting in a 28% and 30% Gross Profit Margin respectively, as compared to \$9.8 million (36%) and \$13.5 million (27%) during the same periods in 2022. Excluding non-cash amounts, the Cost of Finished Cannabis Inventory Sold Margin for the three months ended June 30, 2023 improved to 27% versus 25% in the same period of 2022. This is primarily as a result of a higher proportion of Cannabis 1.0 Products sold by the Company utilizing low-cost cannabis cultivated at Auxly Leamington, and the streamlining of certain Cannabis Products and operating costs.

Realized and unrealized fair value gains and losses reflect accounting treatments associated with Auxly Leamington cultivation activities and sales and are influenced by changes in production, sales and net realizable value assumptions.

Inventory impairments during the second quarter of 2023 of \$1.5 million were associated with certain slower moving SKUs and certain product not meeting quality specifications, a reduction of \$0.3 million from the comparative period. The impairments recognized in the six months ending June 30, 2022 include impairments related to the closure of the Auxly Annapolis facilities.

## **Total Expenses**

Selling, general and administrative expenses (“SG&A”) are comprised of wages and benefits, office and administrative, professional fees, business development, and selling expenses. SG&A expenses were \$8.8 million during the second quarter of 2023, \$4.1 million lower than the second quarter of 2022 primarily due to lower wages and benefits and selling expenses. Year-to-date expenditures of \$18.9 million in 2023 are \$6.7 million lower than the same period in 2022 primarily due to measures taken to reduce overhead in the organization and lower selling expenditures.

Wages and benefits were \$3.3 million for the second quarter of 2023, as compared to \$5.1 million for the same period of 2022. The decrease in expenses was related to the streamlining of operations and support staff for a more focused product portfolio and adjustments to compensation accruals. Year-to-date expenditures of \$8.0 million were lower than those of \$10.7 million during the same period of 2022. The decrease is primarily due to measures taken after the third quarter of 2022 to reduce overhead in the organization.

Office and administrative expenses were \$3.1 million for the period ended June 30, 2023, increasing by \$0.6 million compared to the same period in 2022. The increased expenditures

---

<sup>2</sup> Data provided by HiFyre IQ as at July 31, 2023.

primarily relate to a provision for bad debt related to Fire & Flower Holdings Corp. filing for creditor protection under the Companies' Creditors Arrangement Act and the timing and costs associated with product innovation.

Auxly's professional fees were \$0.6 million during the second quarter of 2023 and \$1.4 million year-to-date which was \$0.5 million and \$0.1 million lower than the same periods in 2022. Professional fees incurred primarily related to accounting fees, regulatory matters, reporting issuer fees, and legal fees associated with certain corporate activities and as a result can fluctuate significantly from one period to the next.

Business development expenses were \$0.2 million for the three and six months ended June 30, 2023 as compared to \$0.1 million and \$0.2 million during the same periods in 2022. These expenses primarily relate to acquisition, business development and travel related expenses.

Selling expenses were \$1.6 million for the three months ended June 30, 2023 and \$3.9 million year-to-date, decreases of \$2.5 million and \$3.1 million over the same periods in 2022, primarily as a result of cost reductions associated with the internalization of the sales team, lower Health Canada fees related to lower revenues, and reduced marketing initiatives.

Equity-based compensation for the three and six months ended June 30, 2023 was \$0.4 million and \$0.8 million respectively. During the same periods of 2022, these amounts were \$2.9 million and \$3.1 million, primarily reflecting the impact of restricted share units ("**RSU**") granted in June 2022, in respect of services provided by employees in 2021.

Depreciation and amortization expenses were \$1.7 million for the period ended June 30, 2023, and \$3.4 million year-to-date decreasing by \$2.2 million and \$5.1 million respectively over the same periods in 2022, primarily as a result of reductions in intangible assets, completion of certain leases and right of use assets, and depreciation associated with disposed assets.

Interest expenses were \$6.5 million and \$12.3 million for the three and six months ended June 30, 2023, an increase of \$1.1 million and \$1.8 million over the same periods in 2022. The increase in expense is primarily a result of the impact of rising interest rates where such obligations are subject to variable charges. Interest expense includes accretion on the convertible debentures and interest paid in kind on the \$123 million Imperial Brands Debenture. Interest payable in cash was approximately \$2.6 million for the three month ended June 30, 2023, an increase of \$0.9 million over the same period in 2022.

### ***Total Other Incomes and Losses***

Total other incomes and losses for the second quarter of 2023 was a net loss of \$1.6 million primarily related to the closure of the Auxly Ottawa facility where the carrying value exceeded the fair value less cost to sell, partially offset by gains due to extensions on unsecured promissory notes. Total other income in the second quarter of 2022 was \$0.9 million primarily resulting from the gains related to the sale of Auxly Annapolis and the extension of the unsecured convertible debentures partially offset by other losses.

Total other incomes and losses for the six months ending June 30, 2023 was a net loss of \$1.7 million compared to a net loss of \$23.1 million in the comparative period, which included first quarter losses associated with the closure of the Auxly Annapolis and Auxly Annapolis OG facilities.

## Net Income and Loss

Net losses for the three months ended June 30, 2023 were \$12.9 million, representing a net loss of \$0.01 per share on a basic and diluted basis. The change in net loss in the second quarter of 2023 as compared to the same period of 2022 was primarily driven by changes in total expenses and reduced gross profits. The net loss of \$54.1 million through six months of 2022 includes the net impact of approximately \$25.7 million related to the closure of the Auxly Annapolis and Auxly Annapolis OG facilities during the first quarter of 2022.

## Adjusted EBITDA

Adjusted EBITDA for the three months ended June 30, 2023 was negative \$1.1 million, an improvement of \$2.9 million over the same period of 2022, primarily as a result of improvements in SG&A partially offset by lower net revenues and increased costs of finished cannabis inventory sold.

## SUMMARY OF QUARTERLY RESULTS

The following table summarizes comparative quarterly results for the last eight quarters.

(000's)	Q2/23	Q1/23	Q4/22	Q3/22	Q2/22	Q1/22	Q4/21	Q3/21
Total net revenues	<b>21,990</b>	23,968	24,681	19,830	27,335	22,626	29,318	24,493
Net losses	<b>(12,863)</b>	(10,249)	(16,056)	(60,102)	(14,289)	(39,846)	(18,376)	(13,527)
Adjusted EBITDA*	<b>(1,078)</b>	138	(783)	(5,776)	(3,995)	(6,324)	(6,043)	(6,099)
Average shares outstanding (000's)	<b>1,002,014</b>	954,014	905,819	901,521	888,267	847,604	829,480	825,613
Per share: Basic & diluted loss	<b>(0.01)</b>	(0.01)	(0.02)	(0.07)	(0.02)	(0.05)	(0.02)	(0.02)

\*Adjusted EBITDA is a Non-IFRS financial measure. Refer to the Non-GAAP Measures section in this MD&A for definitions.

The Company commenced cannabis sales to the Canadian adult recreational market with the legalization of Cannabis 2.0 Products in the fourth quarter of 2019. Since that date, the Company has become a leader in Cannabis 2.0 Products and has continued to introduce new products including Cannabis 1.0 Products to increase total net revenues. To date, net revenues have been seasonally low during the first quarter of any year as a result of retail sales trends which impact the Company's provincial customers' purchasing practices. The Company's expansion into the larger dried flower and pre-roll product categories has contributed to the generally increasing sales trend in what continues to be a volatile sales environment.

Net losses have fluctuated over the eight quarters primarily as a result of other losses which include impairment charges, fair value adjustments and losses on settlement of assets and liabilities. The second quarter of 2023 reflects the impact of the transition of the Company's dried flower and pre-roll cannabis product manufacturing from Auxly Ottawa to Auxly Leamington. The first quarter of 2022 reflects the impact of losses associated with the closure of the Auxly Annapolis and Auxly Annapolis OG facilities, while the third quarter of 2022 reflects charges of \$45 million related to the impairment of goodwill and other assets.

Adjusted EBITDA has fluctuated with changes in total net revenues, changes to product mix with an increase of dried flower and pre-roll Cannabis Products which prior to the acquisition of Auxly Leamington had lower Gross Profit Margins, and the timing of SG&A expenditures, in particular selling expenses. Improvements in the second quarter of 2023 compared to the historical average reflect the impact of lower cultivation costs, improved overall margins and reductions in SG&A during the period.

The increases in average outstanding Shares reflect financing activities (issuance and exchange of Shares, exercise of warrants, options and conversion of convertible debentures).

## TRANSACTIONS WITH RELATED PARTIES

### *Key management and director compensation*

Auxly's key management personnel have authority and responsibility for overseeing, planning, directing and controlling the activities of the Company. Key management personnel include members of the Board of Directors and executive officers. Compensation of key management personnel may include short-term and long-term benefits, as applicable, including salaries, bonuses, equity-based awards or post-employment benefits. Compensation provided to current and key management is as follows:

For the periods ended: (000's)	Three months June 30,		Six months June 30,	
	2023	2022	2023	2022
Short-term benefits	\$ 441	\$ 579	\$ 883	\$ 1,103
Long-term benefits	289	1,654	549	1,758
<b>Total</b>	<b>\$ 730</b>	<b>\$ 2,233</b>	<b>\$ 1,432</b>	<b>\$ 2,861</b>

## LIQUIDITY AND CAPITAL RESOURCES

For the periods ended: (000's)	Three months June 30,		Six months June 30,	
	2023	2022	2023	2022
Cash provided/(used) in operating activities	\$ (5,374)	\$ 1,675	\$ (2,144)	\$ (5,364)
Net change in investments	-	6,000	-	6,000
Net capital expenditures	(490)	(1,048)	(996)	(1,809)
Cash provided/(used) in investing activities	(490)	4,952	(996)	4,191
Net cash provided/(used) from financing activities	(2,420)	(2,528)	(2,939)	6,813
Cash position, at the beginning of the period	16,841	16,295	14,636	14,754
Cash position, end of period	\$ 8,557	\$ 20,394	\$ 8,557	\$ 20,394

Auxly's objectives when managing its liquidity and capital resources are to safeguard its ability to continue as a going concern and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. Auxly considers its capital structure to include debt and shareholders' equity.

Auxly manages its capital structure by preparing rolling cash flow forecasts, monitoring the condition and value of assets available for use as well as those assets being used as security in financing arrangements, seeking flexibility in financing arrangements, and establishing programs to monitor and maintain compliance with terms of financing agreements.

Auxly is dependent on expected business growth, changes in the business environment and capital markets as its source of operating capital and may issue additional Shares or debt, acquire or dispose of assets to maintain or adjust its capital structure.

During the three months ended June 30, 2023, Auxly used \$5.4 million in net cash from operating activities, including the negative impact of \$0.8 million from changes in working capital. Net investing activities for the period ended June 30, 2023, were a use of \$0.5 million primarily related to capital expenditures undertaken at Auxly Leamington. Net financing activities were a use of cash of \$2.4 million for the three months ended June 30, 2023 that reflects the repayment of the Company's loans, lease and other payments.

### *Going concern uncertainty*

The Company's financial statements were prepared on a going concern basis. The going concern basis assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The financial statements do not include any adjustments to the amounts and

classification of assets and liabilities that would be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

On June 30, 2023, the Company had total cash and cash equivalents of \$8.6 million, negative working capital of \$16.8 million, and cash flow used in operating activities of \$2.1 million for the six months ended June 30, 2023. The Company currently will have insufficient cash to fund its operations for the next 12 months if the Company's sales do not improve or if they decline; if the Company's margins do not improve or if they decline; if the Company's selling, general and administrative expenses increase or do not decrease; and/or the Auxly Leamington credit facility of \$46.2 million matures on September 30, 2023, without extension or refinancing. Whether, and when, the Company can attain profitability and positive cash flows from operations is subject to material uncertainty that may cast significant doubt upon the Company's ability to continue as a going concern.

In assessing whether the going concern assumption was appropriate, management took into account all relevant information available about the future including, but not limited to, all relevant information available about the twelve-month period following June 30, 2023. To address its financing requirements, the Company will seek financing through debt and equity financings (which may include use of an at-the-market offering program and/or rights offerings to existing shareholders) and non-core asset sales. The Company will also seek to improve its sales and cash flows by prioritizing certain products and projects with a greater expected return and reducing operating costs by streamlining its operations and support functions. While the Company has been successful in obtaining financing to date, and believes it will be able to obtain sufficient funds in the future and ultimately achieve profitability and positive cash flows from operations, the Company's ability to raise capital may be adversely impacted by: market conditions that have resulted in a lack of normally available financing in the cannabis industry; the Company's ongoing litigation matters; increased competition and price compression across the industry; the industry's inability to quickly eliminate Canada's large illicit cannabis market, and overall negative investor sentiment in light of inflation, global conflict and negative macroeconomic impacts from the COVID-19 pandemic. Accordingly, there can be no assurance that the Company will achieve profitability, or secure financing on terms favourable to the Company or at all.

Should the Company be unable to generate sufficient cash flow from financing and operating activities, the carrying value of the Company's assets could be subject to material adjustments and other adjustments may be necessary to these interim condensed consolidated financial statements should such events impair the Company's ability to continue as a going concern.

Auxly's business is subject to risks and uncertainties that could significantly impair Auxly's ability to raise funds or to generate profits sufficient to meet future obligations, operational, or development needs. See "*Risk Factors*" in this MD&A for information on the risks and uncertainties that could have a negative effect on Auxly's liquidity.

## OUTSTANDING SHARE DATA

Auxly's authorized share capital consists of an unlimited number of Shares. The following table quantifies the number of issued and outstanding Shares and exercisable securities.

	August 11, 2023	June 30, 2023	December 31, 2022
Issued Shares	1,009,008,498	1,009,008,498	913,008,498
Escrowed shares	6,994,190	6,994,190	6,994,190
Outstanding shares	1,002,014,308	1,002,014,308	906,014,308
Outstanding securities			
Warrants	210,510,533	210,510,533	122,510,533
Convertible debentures	196,914,452	196,914,452	205,844,409
Options	22,991,680	23,730,430	24,773,639
Restricted share units	249,944,028	274,134,369	62,088,353

Shares outstanding as at June 30, 2023 increased by approximately 96.0 million to 1,009.0 million primarily as a result of the issuance of equity during the first quarter which also resulted in an equal change in outstanding warrants. The Company repaid \$1.232 million of the principal amount of convertible debentures owing under the amended standby financing agreement as a result of raising additional capital. The number of options declined to 23.7 million as at June 30, 2023 due to employee forfeitures. A total of 213.3 million RSUs were granted to eligible employees and directors on June 30, 2023, such RSUs will each be settled for their cash equivalent on the applicable settlement date, subject to a maximum settlement amount equal to two times the fair value of the RSU on June 30, 2023.

## NON-GAAP MEASURES

The interim condensed consolidated financial statements of Auxly are prepared in accordance with IFRS. Auxly's basis of presentation and significant accounting policies are summarized in detail in notes 2 and 3 of the interim condensed consolidated financial statements for the three and six months ended June 30, 2023, and notes 2 and 3 of the annual consolidated financial statements for the year ended December 31, 2022.

This MD&A makes reference to certain financial measures, including non-GAAP measures that are historical, non-IFRS measures that are forward-looking, and supplementary financial measures. Management uses these financial measures for the purpose of comparison to prior periods and the development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing our business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use the following non-GAAP financial measures: "EBITDA", "Adjusted EBITDA," and the supplementary financial measures of "Cost of Finished Cannabis Inventory Sold Margin", "Gross Profit Margin", and "Debt."

## Financial Measures

### EBITDA and Adjusted EBITDA

These are non-GAAP measures used in the cannabis industry and by the Company to assess operating performance removing the impacts and volatility of non-cash adjustments. The definition may differ by issuer. EBITDA and Adjusted EBITDA used by the Company are reconciled with net loss from continuing operations of the Company, an IFRS measure, in the section “Results of Operations” in this MD&A. The calculation of Adjusted EBITDA is comprised of the net loss from continuing operations of the Company added or subtracted as applicable as provided in the detailed reconciliation found in this MD&A. There are a number of individual financial statement adjustments however, they are inclusive of, interest expense and income, income taxes, depreciation and amortizations, fair value gains or losses, impairments or settlements, foreign exchange, changes in the share of joint venture investments, share based compensation, gains or losses on the sale or disposal of assets and any other unusual items. The Adjusted EBITDA reconciliation is as follows:

(000's)	Q2/23	Q1/23	Q4/22	Q3/22	Q2/22	Q1/22	Q4/21	Q3/21
Net income/(loss)	\$ (12,863)	\$ (10,249)	\$ (16,056)	\$ (60,102)	\$ (14,289)	\$ (39,846)	\$ (18,376)	\$ (13,527)
Interest and accretion expense	6,457	5,808	5,655	5,507	5,336	5,080	4,348	3,932
Interest income	20	(14)	(63)	(105)	(84)	(85)	(308)	(436)
Income tax recovery	-	-	(1,112)	(2,110)	(85)	(2,955)	-	-
Depreciation and amortization included in cost of sales	911	1,120	1,296	681	2,180	1,211	689	386
Depreciation and amortization included in expenses	1,673	1,745	2,791	3,525	3,900	4,600	5,678	2,223
<b>EBITDA</b>	<b>(3,802)</b>	<b>(1,590)</b>	<b>(7,489)</b>	<b>(52,604)</b>	<b>(3,042)</b>	<b>(31,995)</b>	<b>(7,969)</b>	<b>(7,422)</b>
Impairment of biological assets	-	-	-	-	-	704	-	-
Impairment of inventory	1,459	673	2,062	2,014	1,778	4,878	2,194	716
Unrealized fair value loss / (gain) on biological transformation	(4,713)	(4,247)	(2,814)	(7,496)	(11,735)	(6,473)	(1,462)	(352)
Realized fair value loss / (gain) on inventory	3,146	4,639	7,382	8,175	6,898	2,325	904	1
Restructuring related costs	86	165	-	193	-	-	-	-
Equity-based compensation	377	409	429	475	2,916	203	212	55
Fair value loss / (gain) for financial instruments accounted under FVTPL	-	-	-	-	-	-	408	(223)
Impairment of assets	2,588	-	676	42,831	-	23,673	-	60
Non-recurring bad debt expense	780	-	-	-	-	-	-	-
(Gain) / loss on settlement of assets, liabilities and disposals	(1,478)	-	(1,330)	1,574	(163)	-	815	(1,396)
Share of loss on investment in joint venture	-	-	-	-	-	-	(1,387)	3,095
Foreign exchange loss / (gain)	479	89	301	(938)	(647)	361	242	(633)
<b>Adjusted EBITDA</b>	<b>\$ (1,078)</b>	<b>\$ 138</b>	<b>\$ (783)</b>	<b>\$ (5,776)</b>	<b>\$ (3,995)</b>	<b>\$ (6,324)</b>	<b>\$ (6,043)</b>	<b>\$ (6,099)</b>

### Supplementary Financial Measures

#### Cost of Finished Cannabis Inventory Sold Margin

“Cost of Finished Cannabis Inventory Sold Margin” is a supplementary financial measure and is defined as Cost of Finished Cannabis Inventory Sold divided by net revenues.

#### Gross Profit Margin

“Gross Profit Margin” is defined as gross profit divided by net revenues. Gross Profit Margin is a supplementary financial measure.

#### Debt

“Debt” is defined as current and long-term debt and is a supplementary financial measure. It is a useful measure in managing our capital structure and financing requirements.

## COMMITMENTS AND OFF-BALANCE SHEET ARRANGEMENTS

As at June 30, 2023, the Company has entered into certain agreements which commit the Company to future funding following a mutually agreed upon event or events. Commitments have not been described where agreements are insufficiently advanced, unlikely to progress further or amounts are indeterminable.

The Company has funding commitments as follows:

As part of the debt financing provided by a syndicate led by BMO towards the construction of the Auxly Leamington purpose-built greenhouse facility, the Company has guaranteed payments up to \$33 million in the event of default;

Payments of an aggregate of €1.5 million in 2023 and 2024 for cannabis equipment to expand the Company's pre-roll and dried flower capabilities;

Annual payment of approximately \$0.1 million for minimum annual volume requirement with Union Gas, with agreement ending August 1, 2029; and

Annual payment of approximately \$0.1 million until 2024 for guaranteed minimum purchase of bulk carbon dioxide with Air Liquide.

The Company has commitments in respect of long-term debt obligations and leases relating to office spaces, equipment and land which will require payments as follows:

	Remaining in 2023	Fiscal year 2024	Fiscal year 2025	Fiscal year 2026	Thereafter	Total
Lease obligations	\$ 3,189	\$ 3,144	\$ 2,795	\$ 2,775	\$ 10,062	\$ 21,965
Loans payable obligations	47,296	8,183	738	-	-	56,217
Promissory note obligations	600	1,200	1,200	1,200	1,136	5,336
Convertible debenture obligations	472	153,943	-	-	-	154,415
<b>Total</b>	<b>\$ 51,557</b>	<b>\$ 166,470</b>	<b>\$ 4,733</b>	<b>\$ 3,975</b>	<b>\$ 11,198</b>	<b>\$ 237,933</b>

Long-term debt obligations include principal and interest on the Imperial Brands Debenture maturing on September 25, 2024. Subsequent to the quarter-end, Imperial Brands and Auxly entered into an agreement to extend the maturity date of the Imperial Brands Debenture by 24 months from September 25, 2024 to September 25, 2026. The parties anticipate the amendment to come into effect on August 16, 2023. Pursuant to the prior amendments to the Imperial Brands Debenture, interest payable may also be converted to Shares or capitalized and paid at maturity.

Concurrently with the acquisition of Auxly Leamington, Auxly Leamington and Fresh Energy Inc. agreed to complete the transfer of (or part of) a load facility located at 525 County Rd. 14, Mersea RD 9 PH 5 (the "**Transfer**") for which Auxly Leamington shall pay Fresh Energy consideration of:

- an unsecured promissory note in the principal amount of \$3,000 payable in monthly instalments of \$100 for 30 months (the "**Fresh Energy Promissory Note**") and;
- contingent consideration payable of \$500 upon the completion of effecting such Transfer, included in the consideration paid for the acquisition of Auxly Leamington.

In June 2023, the Company entered into an agreement to amend the Fresh Energy Promissory Note whereby the \$500 contingent consideration was added to the remaining principal amount outstanding and the Company shall continue to pay monthly instalments of \$100 until the revised outstanding amount is repaid. As of June 30, 2023, the Company has repaid \$1,780 of principal owing under the Fresh Energy Promissory Note.

In June 2023, the Company entered into an agreement to amend the \$3,400 unsecured promissory note owing to Peter Quiring. Such unsecured promissory note was originally payable in monthly instalments of \$210 for 18 months, starting December 2022. Such note was amended to require the Company to pay monthly instalments of \$100 for 36 months, starting November 2024 and maturing in November 2027. The unsecured promissory note bears interest of 6.00% per annum, with interest accrual starting October 15, 2024.

The Company entered into a brokerage agreement with Kindred Partners Inc. (“**Kindred**”) to act as the Company’s strategic sales agent in September 2019. In October 2022, the brokerage agreement with Kindred was terminated. In January 2023, Kindred commenced arbitration against the Company for an aggregate claim of \$3,442. The Company has filed its defence and counterclaim against Kindred. As at June 30, 2023, the Company has recorded a provision of \$1,235 related to this claim.

In July 2023, the Company reached a settlement, in principle, of the class action commenced against it in the Ontario Superior Court of Justice on March 28, 2019 whereby \$4.0 million will be paid entirely by the Company’s insurance providers to settle all claims in the action. The settlement is being made without any admission or finding of liability and is subject to court approval.

The Company and its subsidiaries are involved in litigation matters arising out of the ordinary course and conduct of its business. Although such matters cannot be predicted with certainty, management does not consider the Company’s exposure to litigation to be material to the consolidated financial statements.

## **CRITICAL ACCOUNTING ESTIMATES**

The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only; or in the period of the change and future periods, if the change affects both.

Areas requiring estimates and judgements are as follows:

### *Impairment of goodwill and intangible assets*

The carrying value of goodwill and intangibles is reviewed annually for impairment or more frequently when there are indicators that impairment may have occurred. The Company’s impairment tests for goodwill and intangible assets are based on the comparison of the carrying amount of the CGU and the recoverable amount, which is the greater of value in use calculations that use a discounted cash flow model and estimated fair value less cost of disposal. The determination of the Company’s CGUs are based on management’s judgement.

If the recoverable amount of the CGU is greater than the carrying amount, the difference is written off as impairment loss. The impairment loss is first allocated to goodwill and the remainder is

allocated to other assets of the CGU subject to the limitation that the carrying amount of an asset should not be reduced below the highest of fair value less cost of disposal, value in use or zero.

The value-in-use calculations employ the following key assumptions: future cash flows, growth projections including economic risk assumptions and estimates of achieving key operating metrics. The cash flows are derived from the Company's budget for the future and do not include restructuring activities that the Company is not yet committed to or significant future investments that will enhance the asset base of the CGU being tested. The recoverable amount is most sensitive to the discount rate used for the discounted cash flow model as well as the expected future cash inflows and the growth rate used for extrapolation purposes. The estimated fair value less cost of disposal is based on assessment of comparable company multiples and precedent transactions.

#### *Biological assets and inventory*

In calculating the value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, harvesting costs, selling costs, average or expected selling prices and list prices, expected yields for the cannabis plants, and oil conversion factors. In calculating final inventory values, management compares the inventory cost to estimated net realizable value. Further information on estimates used in determining the fair value of biological assets is contained in note 6.

#### *Estimated useful lives and depreciation and amortization of property, plant and equipment and intangible assets*

Depreciation and amortization of property, plant and equipment and intangible assets are dependent upon estimates of useful lives, which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that consider factors such as economic and market conditions and the useful lives of assets.

#### *Share-based compensation*

In calculating the equity-based compensation expense, key estimates such as the rate of forfeiture of options and RSUs granted, the expected life of the option and RSU, the volatility of the Company's stock price and the risk-free interest rate are used.

#### *Fair value measurements*

Certain of the Company's assets and liabilities are measured at fair value. In estimating the fair value of Level 2 investments, the Company uses key inputs including the share price of underlying securities, annualized volatility, the risk-free interest rate, the dividend yield, and the expected life of the security. In estimating the fair value of Level 3 investments, the Company uses market-observable data to the extent it is available.

#### *Inputs when using Black-Scholes valuation model*

The estimates used in determining the stock option and warrant fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes

valuation model. Inputs subject to estimates include volatility, forfeiture rates, estimated lives and market rates.

#### *Discount rates*

The discount rates used to calculate the impairment analysis, net present value of notes receivable, the convertible debentures and the notes payable are based on management's best estimates of an approximate industry peer group weighted average cost of capital and management's best estimate of the Company's risk levels.

Changes in the general economic environment could result in significant changes to this estimate.

#### *Convertible instruments*

Convertible debentures are compound financial instruments which are accounted for separately by their components: a financial liability and an equity instrument. The financial liability, which represents the obligation to pay coupon interest on the convertible debentures in the future, is initially measured at its fair value and subsequently measured at amortized cost. The residual amount is accounted for as an equity instrument at issuance.

The identification of convertible debenture components is based on interpretations of the substance of the contractual arrangement and therefore requires judgment from management. The separation of the components affects the initial recognition of the convertible debenture at issuance and the subsequent recognition of interest on the liability component. The determination of the fair value of the liability is also based on a number of assumptions, including contractual future cash flows, discount rates and the presence of any derivative financial instruments.

## **DISCLOSURE AND INTERNAL CONTROLS AND PROCEDURES**

Internal controls over financial reporting (ICFR) and disclosure controls and procedures (DCP) are designed to provide reasonable assurance that material information required to be publicly disclosed is gathered and reported on a timely basis so that appropriate decisions can be made regarding public disclosure.

Auxly's certifying officers have designed, and assessed the design of, ICFR to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financials for external purposes in accordance with IFRS using the criteria set forth in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("**COSO**"). In addition, the Company's certifying officers and its disclosure committee have designed, and assessed the design of, a system of DCP to provide reasonable assurance that (i) material information relating to Auxly, including its consolidated subsidiaries, is made known to them and others; and (ii) information required to be disclosed by Auxly in its annual filings, interim filings and other reports filed or submitted by Auxly under securities legislation is recorded, processed, summarized and reporting within the time periods specified.

There are no material weaknesses relating to the design of either ICFR or DCP at June 30, 2023. There have been no changes to our ICFR during the quarter that has materially affected, or is reasonably likely to materially affect, Auxly's ICFR.

Management does recognize that any controls and procedures no matter how well designed and operated, can only provide reasonable assurance and not absolute assurance of achieving the desired control objectives. In the unforeseen event that lapses in the disclosure or internal controls

and procedures occur and/or mistakes happen, Auxly intends to take whatever steps are necessary to minimize the consequences thereof.

## **CHANGES IN ACCOUNTING POLICIES**

### ***Adoption of new accounting pronouncements***

#### *Amendments to IAS 8, Definition of Accounting Estimates*

In February 2021, the IASB issued amendments to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors (“IAS 8”) to replace the definition of a change in accounting estimates with a definition of accounting estimates. Under the new definition, accounting estimates are “monetary amounts in financial statements that are subject to measurement uncertainty.” The amendments provide clarification to help entities to distinguish between accounting policies and accounting estimates. The amendments are effective for annual reporting periods beginning on or after January 1, 2023. The Company adopted the amendments to IAS 8 with no impact to its interim condensed consolidated financial statements.

#### *Amendments to IAS 12, Deferred Tax related to Assets and Liabilities arising from a Single Transaction*

In May 2021, the IASB issued amendments to IAS 12, Income Taxes (“IAS 12”) to narrow the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offset temporary differences. As a result, companies will need to recognize a deferred tax asset and deferred tax liability for temporary differences arising on initial recognition of transactions such as leases and decommissioning obligations. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and are to be applied retrospectively. The Company adopted the amendments to IAS 12 with no impact to its interim condensed consolidated financial statements.

## **FINANCIAL INSTRUMENTS AND RISK MANAGEMENT**

Auxly’s financial instruments include cash and cash equivalents, restricted cash, short-term investments, accounts receivable, other receivables, deposits, long-term investments, accounts payable and accrued liabilities, promissory notes, loans payable and convertible debentures. Cash and cash equivalents and short-term investments are exposed to credit risk and Auxly reduces its credit risks by placing these instruments with institutions of high credit worthiness. Other receivables relate to outstanding loans and Auxly mitigates the credit risk by entering into agreements and reviewing its exposure to credit risk on a regular basis. Auxly is exposed to liquidity risk with respect to its trade and other payables and Auxly manages liquidity risk by maintaining sufficient cash balances for settlement of financial liabilities on their due dates.

## **RISK FACTORS**

Auxly’s business and structure are subject to a number of risks and uncertainties which could cause future results to differ materially from those described herein, including without limitation, the risk factors discussed in Auxly’s Annual Information Form dated March 30, 2023, which risk factors are incorporated by reference into this document and should be reviewed by all readers. These documents as well as additional information regarding Auxly can be found on SEDAR at [www.sedar.com](http://www.sedar.com).

## FORWARD LOOKING STATEMENTS

This MD&A and the documents incorporated by reference herein contain certain statements which contain "forward-looking information" within the meaning of Canadian securities legislation (each a "forward-looking statement"). No assurance can be given that the expectations in any forward-looking statement will prove to be correct and, as such, the forward-looking statements included in this MD&A should not be unduly relied upon. Forward-looking information is by its nature prospective and requires Auxly to make certain assumptions and is subject to inherent risks and uncertainties. All statements, other than statements of historical fact included in this MD&A, including information that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements. The use of any of the words "anticipates", "plans", "contemplates", "continues", "estimates", "expects", "intends", "proposes", "might", "may", "will", "shall", "projects", "should", "could", "would", "believe", "predict", "forecast", "pursue", "potential", "capable", "budget" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this MD&A may include, but is not limited to, statements pertaining to:

- the ability of the Company to continue as a going concern;
- future liquidity and financial position;
- the Company's growth strategy, targets for future growth and projections of the results of such growth;
- the competitive and business strategies of the Company;
- the intention to grow the business, operations and existing and potential activities of the Company;
- the sufficiency of the Company's resources to fund continued operations;
- the Company's expectations regarding its future sales;
- the impact of the COVID-19 pandemic on the Company's current and future operations;
- the success, and integration of operations, of the entities the Company acquires and the Company's collaborations;
- any ongoing construction, expansions, consolidations, improvements, commissioning of the Company's facilities, equipment or assets, including those of Auxly Charlottetown, Auxly Leamington and Auxly Ottawa, and the timing thereof;
- the intention of the Company to sell the Auxly Ottawa assets and the proposed use of any proceeds;
- the timing and anticipated benefits of the Imperial Brands Debenture amendment;
- inventory and production capacity, including discussions of anticipated yields or plans or potential for expansion of capacity at existing facilities;
- the market for the Company's current and proposed product offerings, as well as the Company's ability to capture and maintain market share;
- the distribution methods expected to be used by the Company to deliver its products;
- the benefits and applications of the Company's current and proposed product offering and expected sales mix thereof;
- development of brands, product diversification and future corporate development;

- the competitive landscape in which the Company operates and the Company's market expertise;
- expectations regarding the Company's ability to raise additional financing to further the Company's investment in the business;
- the applicable legislation, regulations and licensing, and any amendments thereof, related to the cultivation, production, processing, distribution and sale of cannabis products by the Company's subsidiaries and other business interests;
- the ability of the Company to use consumer insights to drive innovation; continuously innovate new cannabis products; and introduce innovative cannabis products to the market;
- the ability of the Company, its subsidiaries and its cultivation partners to cultivate, produce, process, distribute or sell cannabis and cannabis products;
- the ability of the Company to maintain and/or increase its wholesale bulk cannabis sales;
- expectations regarding the Company's licences, including in respect of the grant and maintenance of licences under the Cannabis Act, the Cannabis Regulations and the Industrial Hemp Regulations enacted pursuant to the Cannabis Act, and the permitted activities thereunder;
- the fluctuations in the price of Shares and the market for the Shares;
- the expectation, timing and quantum of future revenues, Cost of Finished Cannabis Inventory Sold Margin, SG&A and of positive Adjusted EBITDA;
- expectations regarding the Company's expansion of sales, operations and investment into foreign jurisdictions;
- the anticipated benefits of the Company's acquisition of Auxly Leamington;
- the performance of the Company's business and operations;
- the ability of the Company to generate cash flow from operations and from financing activities; and
- the Company's competitive position.

The forward-looking statements in this MD&A are based on information currently available and what management believes are reasonable assumptions. Forward-looking statements speak only to such assumptions as of the date of this MD&A. In addition, this MD&A may contain forward-looking statements attributed to third party industry sources, the accuracy of which has not been verified by Auxly. The purpose of forward-looking information is to provide the reader with a description of management's expectations, and such forward-looking information may not be appropriate for any other purpose.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors, that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by the forward-looking statements. A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking statements in this MD&A including, but not limited to, whether:

- the Company will be able to continue as a going concern, will have sufficient working capital and be able to secure adequate financing required in the future on acceptable terms to develop its business and continue operations;

- current and future management will abide by the business objectives and strategies outlined herein;
- the Company will retain and supplement its Board of Directors and management, or otherwise engage consultants and advisors, having knowledge of the industries in which Auxly participates;
- the Company will be able to continue to attract, develop, motivate and retain highly qualified and skilled employees;
- no adverse changes will be made to the regulatory framework governing cannabis, taxes and all other applicable matters in the jurisdictions in which the Company conducts business and any other jurisdiction in which the Company may conduct business in the future;
- the Company will be able to generate cash flow from operations, including, where applicable, the cultivation, production, processing, distribution and sale of Cannabis Products;
- the Company will be able to execute on its business strategy or achieve its goals;
- the Company will be able to maintain and/or grow its market share;
- the Company's subsidiaries will be able to meet the governmental and regulatory requirements necessary to maintain their licences;
- general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same;
- the Company will be able to compete in the cannabis industry;
- there are not materially more closures or lockdowns related to the COVID-19 pandemic;
- the Company will be able to manage anticipated and unanticipated costs;
- the Company will be able to sell the Auxly Ottawa assets and achieve the anticipated cost savings from the closure of the facility;
- the Company is able to implement the Imperial Brands Debenture amendment on the proposed timeline, and whether the expected benefits of the amendment materialize in the manner expected, or at all;
- the Company will be able to successfully integrate Auxly Leamington's operations with its own; and whether the expected benefits of the acquisition materialize in the manner expected, or at all;
- Auxly Leamington will generate sufficient cash flow to satisfy its payment obligations under the amended and restated credit facility; and whether Auxly Leamington will remain in compliance with its operating covenants under the amended and restated credit facility;
- Auxly will be able to maintain effective internal controls over financial reporting and disclosure, controls and procedures;
- there will not be material price compression in the cannabis industry;
- the Company will be able to continue to achieve and maintain its target SG&A expenses;
- the Company will be able to increase and maintain revenues, achieve and maintain positive Adjusted EBITDA and/or achieve and maintain its target Cost of Finished Cannabis Inventory Sold Margin;

- the Company will be able to continue to further expand production capacity and introduce new products and product formats;
- the Company will be able to increase its wholesale bulk cannabis sales;
- the Company will be able to successfully launch and commercialize new brands, create new products and product formats and enter into new markets; and
- there is acceptance and demand for current and future Company products by consumers and provincial purchasers;

Although management believes that the expectations represented in such forward-looking statements are reasonable, there is no assurance that such expectations will prove to have been correct. Auxly cannot guarantee future results, performance or achievements.

Readers are further cautioned that the preparation of financial statements in accordance with IFRS requires management to make certain judgments and estimates that affect the reported amount of assets, liabilities, revenues and expenses. These estimates may impact the financial performance of Auxly when further information becomes available.